A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis.
Adalimumab (ADA) is a monoclonal antibody. Published studies indicate that its use in patients with rheumatoid arthritis can be efficient in providing long-term benefits. The aim of this study is to evaluate the efficacy and safety of ADA for treating rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials that compare subcutaneous doses of ADA 20 mg weekly or 40 mg every other week with placebo, with or without concomitant methotrexate. Only studies of moderate or high quality were included. A meta-analysis was conducted to assess the efficacy (based in changes of American College of Rheumatology ACR criteria) and the safety (based in serious adverse events, serious infections, malignancy and deaths) of ADA use. Withdrawals due to adverse events or lack of efficacy were also evaluated. Eight studies met the inclusion criteria, comprising 2,692 patients. In the efficacy meta-analysis, a greater number of ADA-treated patients relative to those in placebo group achieved ACR20, ACR50 and ACR70 values from 6 months to 2 years of treatment. For safety results, there were no statistically significant differences between the groups. Withdrawals due to adverse events were higher in ADA group relative to the placebo group, and withdrawals due to the lack of efficacy were higher in placebo group relative to the ADA-treated group. This meta-analysis shows a higher efficacy of ADA relative to placebo, but clinicians should be careful regarding adverse events in ADA-treated patients.
Wiens
Astrid
A
Pharmaceutical Practice Research Group, Pharmacy Department, Universidade Federal do Paraná, Av. Pref. Lothário Meissner, 632, Jardim Botânico, Curitiba, Paraná, Brazil. cassyano@ufpr.com.br
Correr
Cassyano Januário
CJ
Venson
Rafael
R
Otuki
Michel Fleith
MF
Pontarolo
Roberto
R
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D010919:Placebos; D000068879:Adalimumab
Ann Rheum Dis. 2004 May;63(5):508-16
15082480
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Ann Rheum Dis. 2006 Jan;65(1):30-4
15901635
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
Mod Rheumatol. 2008;18(3):252-62
18330677
Clin Ther. 2008 Jul;30(7):1375-84
18691998
Ann Rheum Dis. 2003 Dec;62(12):1168-77
14644854
J Rheumatol. 2006 Aug;33(8):1710; author reply 1710
16881134
J Rheumatol. 2003 Dec;30(12):2563-71
14719195
Expert Opin Pharmacother. 2007 Sep;8(13):2089-107
17714062
Clin Immunol. 2008 Feb;126(2):121-36
17916444
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Nat Rev Immunol. 2007 Jun;7(6):429-42
17525752
Nihon Rinsho. 2007 Jul;65(7):1179-84
17642229
Rheumatology (Oxford). 2007 Jul;46(7):1148-52
17478471
Psychol Methods. 2006 Jun;11(2):193-206
16784338
Arthritis Rheum. 2006 Jan;54(1):26-37
16385520
Rheumatology (Oxford). 2000 Jun;39 Suppl 1:43-7
11001379
Rev Assoc Med Bras (1992). 2007 Sep-Oct;53(5):465-70
17952359
J Rheumatol. 2006 Jun;33(6):1075-81
16652437